DOCSLIB.ORG

Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L University of Massachusetts Amherst ScholarWorks@UMass Amherst Open Access Dissertations 5-2012 Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L. Huber University of Massachusetts Amherst, [email protected] Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations Part of the Chemistry Commons Recommended Citation Huber, Kristen L., "Regulation of Caspase-9 by Natural and Synthetic Inhibitors" (2012). Open Access Dissertations. 554. https://doi.org/10.7275/jr9n-gz79 https://scholarworks.umass.edu/open_access_dissertations/554 This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact [email protected]. REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Submitted to the Graduate School of the University of Massachusetts Amherst in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY MAY 2012 Chemistry © Copyright by Kristen L. Huber 2012 All Rights Reserved REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Approved as to style and content by: _________________________________________ Jeanne A. Hardy, Chair _________________________________________ Lila M. Gierasch, Member _________________________________________ Robert M. Weis, Member _________________________________________ Peter Chien, Member ______________________________________ Craig T. Martin, Department Head Department of Chemistry DEDICATION For my mother, Elizabeth Huber, who taught me perseverance and to always follow my dreams, no matter how big or small For my father, Kenneth Huber, who taught me to believe in myself and to remember you can always find a new beginning in tomorrow For my sister, Elyse Huber, for being the person who inspires me every single day and who taught me to be proud of who I am ACKNOWLEDGMENTS To my mentor, Professor Jeanne Hardy, I thank you for guidance and support over this long and somewhat bumpy road. We have both grown in many ways since our first year here at UMass; you as a mentor, me as a budding scientist and both as individuals. Between the memories of our scientific travels and your enthusiastic high fives, you have truly made this an experience I will never forget. To my committee, Dr. Lila Gierasch, Dr. Bob Weis and Dr. Peter Chein, you have pushed me to be a better scientist by teaching me to think outside the box and appreciate the meaning of testing a hypothesis. I thank you. To the Hardy Lab members, my scientific family, both past and present, you will always be held near and dear to my heart. From the Monday morning sports talk to the mid week frustrations followed up by the Friday fireside chats and all of the fun times, you filled my days with laughter and enjoyment. Thank you for being the everyday rock I could always count on. To my all my friends, you have been a shoulder to lean on and a breath of fresh air when I needed it most. To Mike Wilson Jr. and Shannon Coates Flagg, thank you for always listening, understanding, and making me smile. This road would have been difficult without all of your support so let the good times roll! And last but certainly not least, to my family, I would not be where I am today or the person I am today without your unconditional love, support, and understanding. Thank you, not only for being my biggest fans but for supporting me through the tough times and keeping me grounded as a person. Mama, thank you for encouraging me to not only dance to the beat of a different drummer but to polka whenever I had the chance. Pappy, thank you for always finding the right words to make me feel at ease and giving me the encouragement to always stand up for what I believe in. Elyse, my partner in crime, thank you for teaching me all of the important life skills I needed to accomplish my goals. You have taught me how to think on my feet, especially when getting framed for taking cookies out of the kitchen, how to accept constructive criticism by convincing me there is always room for improvement, particularly when it comes to my touchdown dance moves, and patience by forgetting to find me when playing hide-n-go-seek. We are truly two peas in a pod, SBN! I love you all! “You have brains in your head. You have feet in your shoes You can steer yourself any direction you choose. You're on your own. And you know what you know. And YOU are the guy who'll decide where to go.” Oh, the Places You’ll Go! -Dr. Seuss v ABSTRACT REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS MAY 2012 KRISTEN L. HUBER, B.S., QUINNIPIAC UNIVERSITY Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST Directed by: Professor Jeanne A. Hardy Tight regulation of caspase-9, a key initiator of apoptosis, is required to uphold cellular homeostasis. Although it is controlled on a multifactorial level, misregulation of this process does occur, which is a characteristic of a variety of diseases from ischemic injury to cancer. Therefore it remains important to gain a detailed understanding of the mechanisms behind native caspase-9 regulatory pathways and harness these mechanisms for therapeutic purposes. Based on known mechanisms, such as the unique inhibitory complex of caspase- 9 and XIAP-BIR3, development of synthetic regulators can be envisioned, while other mechanisms such as zinc-mediated inhibition and CARD activation of caspse-9 remain undefined. Intrigued by the multiple ways to control caspase-9’s activity, we sought after designing synthetic caspase-9 inhibitors in addition to defining the mechanistic details metal regulation and CARD domain activation. We report the first stabilized α-helical peptides that harness the native regulatory mechanism of caspase-9 and the BIR3 domain which lead to the understanding of the importance of exosites in inhibitory complexes. Our studies also revealed that there are two distinct zinc binding sites, one at the active site and another at a novel zinc binding site of yet unknown function in caspase-9 however this site may have the potential to vi control caspase-6 based on its regulatory mechanism. Furthermore, an interaction was discovered between CARD and the catalytic core of caspase-9 in the presence of a properly formed substrate binding groove, a potential mechanism utilized by the apoptosome for activation of the enzyme. All in all, the regulation of caspase-9 occurs on a variety of levels that requires almost every surface of the enzyme. Through exploring these underlying molecular details behind the various mechanisms, not only has the field of caspase-9 regulation mechanisms been extended, essential information was gained for further pursuit in an advancement towards the design of caspase-9 activators and inhibitors. vii TABLE OF CONTENTS Page ACKNOWLEDGMENTS ...................................................................................................v ABSTRACT ....................................................................................................................... vi LIST OF TABLES ........................................................................................................... xiii LIST OF FIGURES ......................................................................................................... xiv CHAPTER I. APOPTOSIS, DISEASE AND THE REGULATION OF CASPASE-9 .........................1 1.1. The Roles of Apoptosis in Disease ...................................................................1 1.2. Caspases: Facilatators of Apoptosis..................................................................4 1.3. Caspase Active Site and Catalytic Mechanism .................................................6 1.4. Apoptotic Pathways ..........................................................................................9 1.5. Natural Regulation of Caspase-9 ....................................................................11 1.6. Synthetic Regulation of Caspase-9 .................................................................15 1.7. Caspase-9 and Its Role in Disease ..................................................................19 1.8. Refrences.........................................................................................................21 II. ROBUST PRODUCTION OF A LIBRARY OF CASPASE-9 INHIBITOR PEPTIDES USING METHODOLOGICAL SYNCHRONIZATION .........................30 2.1. Introduction .....................................................................................................31 2.2. Results .............................................................................................................34 2.2.1. Construction of Peptide-Fusion Expression Vector and aPP Variants ....................................................................................34 2.2.2. Expression and Purification of a Recombinant Peptide Library ......36 2.3. Discussion .......................................................................................................41 2.4. Materials and Methods ....................................................................................45 viii 2.4.1. Cloning of Recombinant Peptide-Fusion Variants ..........................45 2.4.2. Expression and Purification of Recombinant Peptide-Fusion Variants ...................................................................46 2.4.3. Expression
Load more

Recommended publications
  • Manner Via Caspase-8 in an RIP3
    Cutting Edge: FAS (CD95) Mediates Noncanonical IL-1 β and IL-18 Maturation via Caspase-8 in an RIP3-Independent Manner This information is current as of October 2, 2021. Lukas Bossaller, Ping-I Chiang, Christian Schmidt-Lauber, Sandhya Ganesan, William J. Kaiser, Vijay A. K. Rathinam, Edward S. Mocarski, Deepa Subramanian, Douglas R. Green, Neal Silverman, Katherine A. Fitzgerald, Ann Marshak-Rothstein and Eicke Latz Downloaded from J Immunol 2012; 189:5508-5512; Prepublished online 9 November 2012; doi: 10.4049/jimmunol.1202121 http://www.jimmunol.org/content/189/12/5508 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2012/11/12/jimmunol.120212 Material 1.DC1 References This article cites 30 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/189/12/5508.full#ref-list-1 by guest on October 2, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved.
    [Show full text]
  • The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies
    Hindawi Publishing Corporation International Journal of Cell Biology Volume 2010, Article ID 215158, 21 pages doi:10.1155/2010/215158 Review Article TheRoleofCyclooxygenase-2inCellProliferationandCell Death in Human Malignancies Cyril Sobolewski,1 Claudia Cerella,1 Mario Dicato,1 Lina Ghibelli,2 and Marc Diederich1 1 LaboratoiredeBiologieMol´eculaire et Cellulaire du Cancer, Hopitalˆ Kirchberg, 9 rue Edward Steichen, 2540 Luxembourg, Luxembourg 2 Dipartimento di Biologia, Universita` di Roma di Roma Tor Vergata, Via Ricerca Scientifica snc, 00133 Rome, Italy Correspondence should be addressed to Marc Diederich, [email protected] Received 16 July 2009; Accepted 18 December 2009 Academic Editor: Simone Fulda Copyright © 2010 Cyril Sobolewski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. It is well admitted that the link between chronic inflammation and cancer involves cytokines and mediators of inflammatory pathways, which act during the different steps of tumorigenesis. The cyclooxygenases (COXs) are a family of enzymes, which catalyze the rate-limiting step of prostaglandin biosynthesis. This family contains three members: ubiquitously expressed COX- 1, which is involved in homeostasis; the inducible COX-2 isoform, which is upregulated during both inflammation and cancer; and COX-3, expressed in brain and spinal cord, whose functions remain to be elucidated. COX-2 was described to modulate cell proliferation and apoptosis mainly in solid tumors, that is, colorectal, breast, and prostate cancers, and, more recently, in hematological malignancies. These findings prompt us to analyze here the effects of a combination of COX-2 inhibitors together with different clinically used therapeutic strategies in order to further improve the efficiency of future anticancer treatments.
    [Show full text]
  • Induced Apoptosis
    APOPTOSIS INDUCTION AND IMMUNOTHERAPY-HOW TO IMPROVE RESULTS OF IMMUNOTHERAPY C/ Professor Peter Hersey University of Newcastle NSW Australia IMMUNOTHERAPY DEPENDS ON INDUCTION OF APOPTOSIS! • IF WE UNDERSTAND THE RESISTANCE MECHANISMS AGAINST APOPTOSIS WE CAN TARGET THESE AND IMPROVE THE RESULTS OF IMMUNOTHERAPY CELL KILLING MECHANISMS USED BY LYMPHOCYTES DEPEND ON INDUCTION OF APOPTOSIS 1. Granzyme – Perforin Mediated Killing CD8 CTL (CD4 CTL) NK Cells and ADCC 2.Death Ligand Mediated Killing TRAIL, FasL, TNF CD4 T Cells Monocytes, Dendritic Cells CURRENTCURRENT CONCEPTSCONCEPTS ININ APOPTOSISAPOPTOSIS TRAIL, Granz B P53.-NOXA, BID CYTOSKELETON PUMA,BAD,BID BIM,BMF Bcl-2,Bcl-xL.Mcl-1 ER Stress, Bik,PUMA,Noxa Bax,Bak Mitochondria Smac,Omi Cyto c, Casp 9 IAPs Classical Pathway Effector Caspases 3,7 MITOCHONDRIAL PATHWAYS TO APOPTOSIS ARE REGULATED BY BCL-2 FAMILY PROTEINS • Pro-apoptotic BH3 only damage sensor proteins (Bid, Bik,Bim, Bmf, Noxa,Puma,Bad,Hrk) • Pro-apoptotic multidomain proteins: BAX, BAK • Anti-apoptotic proteins: BCL-2, BCL-Xl, MCL-1, Bcl-W,A1 WE ALREADY HAVE AGENTS THAT TARGET THE ANTI APOPTOTIC PROTEINS! Targetting Anti Apoptotic Proteins • Genasense against Bcl-2. • Inhibition of production of the IAP protein Survivin YM155 (Astellas Pharm • BH3 mimics that bind Bcl-2 proteins(Abbott ABT-737) Targetting Anti-Apoptotic Proteins • AT-101 (Gossypol) Oral inhibitor of Bcl-2 Bcl- XL,Mcl-1 . Ascenta Therapeutics • TW37- Small mw mimic of Bim that inhibits Bcl-2, Bcl-XL,Mcl-1. Univ Michigan • Obatoclax (GX015-070) Small mw BH3 mimic . Inhibits Bcl-2,Bcl-XL,Mcl-1. (Gemin X) TRAIL INDUCED KILLING REQUIRES DEATH RECEPTORS! TRAIL Induces Apoptosis in the Majority of Melanoma Cell Lines 100 90 80 70 60 50 40 30 % Apoptotic Cells % Apoptotic 20 10 0 1 2 3 4 5 6 7 8 9 101112131415161718192021222324252627282930 Melanoma Cell Lines TRAIL-R1 & R2 Expression Correlates with Degree of Apoptosis L I A 120 120 R T 100 100 y b 80 80 d e 60 60 c u d 40 40 n I s 20 20 si o 0 0 t p -20 o -20 p A -10 10 30 50 70 90 -10 10 30 50 70 90 % TRAIL-R1 TRAIL-R2 Zhang et al.
    [Show full text]
  • Biochemical Society Focused Meetings Proteases A
    ORE Open Research Exeter TITLE Proteases and caspase-like activity in the yeast Saccharomyces cerevisiae. AUTHORS Wilkinson, D; Ramsdale, M JOURNAL Biochemical Society Transactions DEPOSITED IN ORE 18 November 2013 This version available at http://hdl.handle.net/10871/13957 COPYRIGHT AND REUSE Open Research Exeter makes this work available in accordance with publisher policies. A NOTE ON VERSIONS The version presented here may differ from the published version. If citing, you are advised to consult the published version for pagination, volume/issue and date of publication Biochemical Society Transactions (2011) XX, (XX-XX) (Printed in Great Britain) Biochemical Society Focused Meetings Proteases and caspase-like activity in the yeast Saccharomyces cerevisiae Derek Wilkinson and Mark Ramsdale1 Biosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, EX4 4QD Key words: Programmed cell death, apoptosis, necrosis, proteases, caspases, Saccharomyces cerevisiae. Abbreviations used: PCD, programmed cell death; ROS, reactive oxygen species; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ER, endoplasmic reticulum; MS, mass spectrometry. 1email [email protected] Abstract A variety of proteases have been implicated in yeast PCD including the metacaspase, Mca1 and the separase Esp1, the HtrA-like serine protease Nma111, the cathepsin-like serine carboxypeptideases and a range of vacuolar proteases. Proteasomal activity is also shown to have an important role in determining cell fate, with both pro- and anti-apoptotic roles. Caspase-3, -6- and -8 like activities are detected upon stimulation of yeast PCD, but not all of this activity is associated with Mca1, implicating other proteases with caspase-like activity in the yeast cell death response.
    [Show full text]
  • Apoptotic Threshold Is Lowered by P53 Transactivation of Caspase-6
    Apoptotic threshold is lowered by p53 transactivation of caspase-6 Timothy K. MacLachlan*† and Wafik S. El-Deiry*‡§¶ʈ** *Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, and Departments of ‡Medicine, §Genetics, ¶Pharmacology, and ࿣Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Communicated by Britton Chance, University of Pennsylvania School of Medicine, Philadelphia, PA, April 23, 2002 (received for review January 11, 2002) Little is known about how a cell’s apoptotic threshold is controlled Inhibition of the enzyme reduces the sensitivity conferred by after exposure to chemotherapy, although the p53 tumor suppres- overexpression of p53. These results identify a pathway by which sor has been implicated. We identified executioner caspase-6 as a p53 is able to accelerate the apoptosis cascade by loading the cell transcriptional target of p53. The mechanism involves DNA binding with cell death proteases so that when an apoptotic signal is by p53 to the third intron of the caspase-6 gene and transactiva- received, programmed cell death occurs rapidly. tion. A p53-dependent increase in procaspase-6 protein level al- lows for an increase in caspase-6 activity and caspase-6-specific Materials and Methods Lamin A cleavage in response to Adriamycin exposure. Specific Western Blotting and Antibodies. Immunoblotting was carried out by inhibition of caspase-6 blocks cell death in a manner that correlates using mouse anti-human p53 monoclonal (PAb1801; Oncogene), with caspase-6 mRNA induction by p53 and enhances long-term rabbit anti-human caspase-3 (Cell Signaling, Beverly, MA), mouse survival in response to a p53-mediated apoptotic signal.
    [Show full text]
  • Inhibitor of Apoptosis Proteins As Therapeutic Targets in Multiple Myeloma
    Leukemia (2014) 28, 1519–1528 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma V Ramakrishnan1, U Painuly1,2, T Kimlinger1, J Haug1, SV Rajkumar1 and S Kumar1 The inhibitor of apoptosis (IAP) proteins have a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple myeloma (MM) by using a Smac (second mitochondria-derived activator of caspases)-mimetic LCL161. We observed that LCL161 was able to potently induce apoptosis in some MM cell lines but not in others. Examining the levels of X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitor of apoptosis protein 1 (cIAP1) and cellular inhibitor of apoptosis protein 2 (cIAP2) post LCL161 treatment indicated clear downregulation of both XIAP activity and cIAP1 levels in both the sensitive and less sensitive (resistant) cell lines. cIAP2, however, was not downregulated in the cell line resistant to the drug. Small interfering RNA-mediated silencing of cIAP2 significantly enhanced the effect of LCL161, indicating the importance of downregulation of all IAPs simultaneously for induction of apoptosis in MM cells. LCL161 induced marked up regulation of the Jak2/Stat3 pathway in the resistant MM cell lines. Combining LCL161 with a Jak2-specific inhibitor resulted in synergistic cell death in MM cell lines and patient cells. In addition, combining LCL161 with death- inducing ligands clearly showed that LCL161 sensitized MM cells to both Fas-ligand and TRAIL.
    [Show full text]
  • Α Are Regulated by Heat Shock Protein 90
    The Levels of Retinoic Acid-Inducible Gene I Are Regulated by Heat Shock Protein 90- α Tomoh Matsumiya, Tadaatsu Imaizumi, Hidemi Yoshida, Kei Satoh, Matthew K. Topham and Diana M. Stafforini This information is current as of October 2, 2021. J Immunol 2009; 182:2717-2725; ; doi: 10.4049/jimmunol.0802933 http://www.jimmunol.org/content/182/5/2717 Downloaded from References This article cites 44 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/182/5/2717.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Levels of Retinoic Acid-Inducible Gene I Are Regulated by Heat Shock Protein 90-␣1 Tomoh Matsumiya,*‡ Tadaatsu Imaizumi,‡ Hidemi Yoshida,‡ Kei Satoh,‡ Matthew K. Topham,*† and Diana M. Stafforini2*† Retinoic acid-inducible gene I (RIG-I) is an intracellular pattern recognition receptor that plays important roles during innate immune responses to viral dsRNAs.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • The Role of Caspase-2 in Regulating Cell Fate
    cells Review The Role of Caspase-2 in Regulating Cell Fate Vasanthy Vigneswara and Zubair Ahmed * Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK; [email protected] * Correspondence: [email protected] Received: 15 April 2020; Accepted: 12 May 2020; Published: 19 May 2020 Abstract: Caspase-2 is the most evolutionarily conserved member of the mammalian caspase family and has been implicated in both apoptotic and non-apoptotic signaling pathways, including tumor suppression, cell cycle regulation, and DNA repair. A myriad of signaling molecules is associated with the tight regulation of caspase-2 to mediate multiple cellular processes far beyond apoptotic cell death. This review provides a comprehensive overview of the literature pertaining to possible sophisticated molecular mechanisms underlying the multifaceted process of caspase-2 activation and to highlight its interplay between factors that promote or suppress apoptosis in a complicated regulatory network that determines the fate of a cell from its birth and throughout its life. Keywords: caspase-2; procaspase; apoptosis; splice variants; activation; intrinsic; extrinsic; neurons 1. Introduction Apoptosis, or programmed cell death (PCD), plays a pivotal role during embryonic development through to adulthood in multi-cellular organisms to eliminate excessive and potentially compromised cells under physiological conditions to maintain cellular homeostasis [1]. However, dysregulation of the apoptotic signaling pathway is implicated in a variety of pathological conditions. For example, excessive apoptosis can lead to neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, whilst insufficient apoptosis results in cancer and autoimmune disorders [2,3]. Apoptosis is mediated by two well-known classical signaling pathways, namely the extrinsic or death receptor-dependent pathway and the intrinsic or mitochondria-dependent pathway.
    [Show full text]
  • 505.Full.Pdf
    Pseudomonas aeruginosa Delays Kupffer Cell Death via Stabilization of the X-Chromosome-Linked Inhibitor of Apoptosis Protein This information is current as of September 26, 2021. Alix Ashare, Martha M. Monick, Amanda B. Nymon, John M. Morrison, Matthew Noble, Linda S. Powers, Timur O. Yarovinsky, Timothy L. Yahr and Gary W. Hunninghake J Immunol 2007; 179:505-513; ; doi: 10.4049/jimmunol.179.1.505 Downloaded from http://www.jimmunol.org/content/179/1/505 References This article cites 44 articles, 21 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/179/1/505.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 26, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Pseudomonas aeruginosa Delays Kupffer Cell Death via Stabilization of the X-Chromosome-Linked Inhibitor of Apoptosis Protein1 Alix Ashare,2* Martha M.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Blockade of BCL-2 Proteins Efficiently Induces Apoptosis in Progenitor
    Leukemia (2016) 30, 112–123 © 2016 Macmillan Publishers Limited All rights reserved 0887-6924/16 www.nature.com/leu ORIGINAL ARTICLE Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients S Jilg1, V Reidel1, C Müller-Thomas1, J König1, J Schauwecker2, U Höckendorf1, C Huberle1, O Gorka3, B Schmidt4, R Burgkart2, J Ruland3, H-J Kolb1, C Peschel1, RAJ Oostendorp1, KS Götze1 and PJ Jost1 Deregulated apoptosis is an identifying feature of myelodysplastic syndromes (MDS). Whereas apoptosis is increased in the bone marrow (BM) of low-risk MDS patients, progression to high-risk MDS correlates with an acquired resistance to apoptosis and an aberrant expression of BCL-2 proteins. To overcome the acquired apoptotic resistance in high-risk MDS, we investigated the induction of apoptosis by inhibition of pro-survival BCL-2 proteins using the BCL-2/-XL/-W inhibitor ABT-737 or the BCL-2-selective inhibitor ABT-199. We characterized a cohort of 124 primary human BM samples from MDS/secondary acute myeloid leukemia (sAML) patients and 57 healthy, age-matched controls. Inhibition of anti-apoptotic BCL-2 proteins was specifically toxic for BM cells from high-risk MDS and sAML patients, whereas low-risk MDS or healthy controls remained unaffected. Notably, ABT-737 or ABT-199 treatment was capable of targeting the MDS stem/progenitor compartment in high-risk MDS/sAML samples as shown by the reduction in CD34+ cells and the decreased colony-forming capacity. Elevated expression of MCL-1 conveyed resistance against both compounds. Protection by stromal cells only partially inhibited induction of apoptosis.
    [Show full text]